Development of V2-deleted trimeric envelope vaccine candidates from human immunodeficiency virus type 1 (HIV-1) subtypes B and C

Microbes Infect. 2005 Nov;7(14):1386-91. doi: 10.1016/j.micinf.2005.07.018. Epub 2005 Sep 20.

Abstract

The urgent need for a vaccine against HIV/AIDS requires that multiple strategies be employed and evaluated in a clinical setting. V2-loop deleted trimeric envelope (Env) immunogens (protein and DNA) from subtypes B and C human immunodeficiency virus type 1 (HIV-1) strains were produced for ongoing and future clinical evaluations with other HIV antigens, adjuvants and deliveries.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS Vaccines / genetics
  • AIDS Vaccines / immunology*
  • Animals
  • Clinical Trials, Phase I as Topic
  • Drug Evaluation, Preclinical
  • Enzyme-Linked Immunosorbent Assay
  • Gene Products, env / chemistry
  • Gene Products, env / genetics
  • Gene Products, env / immunology*
  • HIV Antibodies / blood*
  • HIV Infections / prevention & control
  • HIV-1 / classification
  • HIV-1 / genetics
  • HIV-1 / immunology*
  • Humans
  • Neutralization Tests
  • Rabbits
  • Vaccines, DNA / genetics
  • Vaccines, DNA / immunology
  • Vaccines, Synthetic / genetics
  • Vaccines, Synthetic / immunology
  • env Gene Products, Human Immunodeficiency Virus

Substances

  • AIDS Vaccines
  • Gene Products, env
  • HIV Antibodies
  • Vaccines, DNA
  • Vaccines, Synthetic
  • env Gene Products, Human Immunodeficiency Virus
  • gp140 envelope protein, Human immunodeficiency virus 1